Search research articles
Contact Us
Filters
Showing results (131-140 of 155) with videos related to
Page
of 16
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
November 2, 2018
Amygdalar Metabolic Activity Independently Associates With Progression of Visceral Adiposity
Amorina Ishai, Michael T Osborne, Brian Tung, et al.
Rheumatology and Therapy
|
January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.
RMD Open
|
October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
Jonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 17, 2024
The monocyte cell surface is a unique site of autoantigen generation in rheumatoid arthritis
Mekha A Thomas, Pooja Naik, Hong Wang, et al.
Annals of the Rheumatic Diseases
|
September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases
|
January 31, 2023
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, et al.
ACR Open Rheumatology
|
May 1, 2021
Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
Jon T Giles, Pamela M Rist, Katherine P Liao, et al.
Annals of the Rheumatic Diseases
|
November 30, 2022
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis
Daniel H Solomon, Jon T Giles, Katherine P Liao, et al.
Annals of the Rheumatic Diseases
|
September 24, 2025
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease
Jon T Giles, Christina Charles-Schoeman, Maya H Buch, et al.
Journal of the American Geriatrics Society
|
August 5, 2022
Analysis of lumbar spine stenosis specimens for identification of amyloid
Mathew S Maurer, Dia Smiley, Eli Simsolo, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 155) with videos related to
Sort By:
Page
of 16
The Journal of Clinical Endocrinology and Metabolism
|
November 2, 2018
Amygdalar Metabolic Activity Independently Associates With Progression of Visceral Adiposity
Amorina Ishai, Michael T Osborne, Brian Tung, et al.
Rheumatology and Therapy
|
January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.
RMD Open
|
October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
Jonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 17, 2024
The monocyte cell surface is a unique site of autoantigen generation in rheumatoid arthritis
Mekha A Thomas, Pooja Naik, Hong Wang, et al.
Annals of the Rheumatic Diseases
|
September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases
|
January 31, 2023
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, et al.
ACR Open Rheumatology
|
May 1, 2021
Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
Jon T Giles, Pamela M Rist, Katherine P Liao, et al.
Annals of the Rheumatic Diseases
|
November 30, 2022
Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis
Daniel H Solomon, Jon T Giles, Katherine P Liao, et al.
Annals of the Rheumatic Diseases
|
September 24, 2025
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease
Jon T Giles, Christina Charles-Schoeman, Maya H Buch, et al.
Journal of the American Geriatrics Society
|
August 5, 2022
Analysis of lumbar spine stenosis specimens for identification of amyloid
Mathew S Maurer, Dia Smiley, Eli Simsolo, et al.
Page
of 16